CYP CYP2C1919基因检测在氯吡格雷个体化用药中的应用价值

Application Value of CYP2C19 Gene Detection in Individualized Use of Clopidogrel

目的探讨CYP2C19基因检测在氯吡格雷个体化用药中的应用价值。方法选取医院2023年5月至10月收治的冠状动脉介入术(PCI)后使用氯吡格雷的患者90例,根据CYP2C19基因检测结果指导患者用药,比较不同基因型患者心脏管疾病不良反应发生率。结果慢代谢型心力衰竭、心律失常、冠状动脉粥样硬化性心脏病及脑出血发生率显著高于其他类型(P<0.05);而中间代谢型心脑血管疾病发生率显著高于快代谢基因型(P<0.05);CYP2C19基因不同分型下药物皮疹结肠炎、胃肠道出血及粒细胞缺乏发生率无显著差异(P>0.05)。结论CYP2C19基因检测可评估患者机体药物代谢情况,可用于调整氯吡格雷的用药方案。

Objective To investigate the application value of CYP2C19 gene detection in individualized use of clopidogrel.Methods Ninety patients who underwent percutaneous coronary intervention(PCI)and used clopidogrel in the hospital from May to October 2023 were selected.Based on the results of CYP2C19 gene testing,patients were guided to take medicines,and the incidence of adverse reactions to cardiovascular diseases in patients with different genotypes was compared.Results The incidence of slow metabolic heart failure,arrhythmia,coronary atherosclerotic heart disease and cerebral hemorrhage was significantly higher than that of other types(P<0.05).The incidence of intermediate metabolic cardiovascular and cerebrovascular diseases was significantly higher than that of fast metabolic genotypes(P<0.05).There was no significant difference in the incidence of drug-induced rash,colitis,gastrointestinal bleeding,and granulocyte deficiency among different subtypes of CYP2C19 gene(P>0.05).Conclusion CYP2C19 gene testing can evaluate the drug metabolism of patients,which is beneficial for adjusting the medication regimen of clopidogrel.